Trade margin rationalisation

Indian Economy glossary

Also called: TMR · Topic: Markets, Equilibrium and Government Intervention · NCERT: Beyond NCERT

Meaning

Trade margin rationalisation (TMR) means the government caps the trade margin on a drug or medical device. The trade margin is the gap between the Price to Distributor (PTD), the price the company charges its first buyer, and the Maximum Retail Price (MRP) the patient pays. TMR is used for non-scheduled products (those with no government ceiling price), under the emergency power in Para 19 of DPCO 2013. It does not touch the company's own selling price. It only cuts what the supply chain adds on top of that price.

  • Trade margin = MRP − PTD
  • Trade margin % = (MRP − PTD) ÷ PTD × 100
  • Under a TMR cap: MRP ≤ PTD × (1 + cap %)

It matters because ceiling prices reach only a small part of the drug market. About 82% of market value (FY25) is non-scheduled. TMR is a middle path that brings this large segment under some price discipline without full price control.

Explanation

How a drug's price is built up

  • Three price points along the chain:
  • PTD (Price to Distributor): what the manufacturer charges the distributor.
  • PTR (Price to Retailer): what the chemist pays the distributor.

  • MRP: the highest price the patient can be charged.

  • Who earns the trade margin: distributors, stockists and chemists, i.e. the middlemen between factory and patient.

  • What TMR does: it limits the total gap from PTD to MRP. The company must then print a lower MRP.
  • What TMR does not do: it does not check whether the PTD is fair. NPPA has no power to audit what a drug actually costs to make. DPCO 2013 has "no provision" for using cost-audit data.

Why non-scheduled drugs need a separate tool

  • Scheduled drugs are the NLEM medicines placed in Schedule-I of DPCO 2013. NPPA fixes ceiling prices for them.
  • Non-scheduled drugs are everything else:
  • the company sets the launch price itself;

  • the MRP may rise by at most 10% in 12 months.

  • Where the problem sits:

  • About 4% of the non-scheduled market has markups above 100% of PTD.
  • High-priced cancer drugs are one such segment.

  • Hospitals and chemists giving discounts of 20% to 60% on MRP show that big margins are built into the printed price.

  • Why the cap is selective: TMR is aimed at the few segments with very high margins, not at the whole market.

Worked example (hypothetical numbers)

  • Suppose a cancer injection has PTD = ₹1,000 and MRP = ₹3,000.
  • Trade margin = ₹3,000 − ₹1,000 = ₹2,000.

  • Trade margin % = 2,000 ÷ 1,000 × 100 = 200%.

  • Now apply a 30% cap, the rate used in the 2019 pilot:

  • New maximum MRP = ₹1,000 × 1.30 = ₹1,300.

  • The patient's price falls by about 57%. The manufacturer still gets ₹1,000.

  • The lesson: the higher the original markup, the bigger the cut. That is why cancer drugs see such large falls, e.g. Bevacizumab 100 mg/4 ml fell from ₹21,767.70 to ₹5,930.13 (2026).

What makes TMR stronger or weaker

  • Stronger when:
  • the markup is large compared with PTD;

  • patients buy at the full MRP (often patients far from big hospitals).

  • Weaker when:

  • patients already got hospital discounts or bought at AMRIT pharmacies, which sell up to 50% below MRP. Their real saving is smaller than the headline figure;
  • companies set a high PTD in the first place, because TMR cannot touch it;
  • old stock keeps being sold at the pre-revised MRP.

In India

  • Regulator: NPPA (National Pharmaceutical Pricing Authority), constituted by a Government Resolution on 29 Aug 1997. It is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
  • Legal basis:
  • DPCO 2013, issued under Section 3 of the Essential Commodities Act, 1955;
  • TMR is carried out under Para 19, which allows prices to be fixed in public interest in extraordinary circumstances;

  • violations can be penalised under Section 7 of the ECA.

  • How TMR has been used:

Year Coverage Margin cap / result
2019 (27 Feb) 42 non-scheduled anti-cancer drugs Trade margin capped at 30%. 526 brands fell by about 50% on average, saving about ₹984 crore a year
2021 (June–July) 6 COVID-related devices (oxygen concentrators, pulse oximeters, BP monitors, nebulisers, digital thermometers, glucometers) Margin capped at 70% of PTD
2026 137 non-scheduled anti-cancer drugs Revised MRPs for 543 brands, effective 9 Nov 2026
  • Devices: all medical devices came under DPCO 2013 from 1 Apr 2020, which is why TMR could be applied to devices.
  • Gap in the framework: DPCO 2013 has no permanent provision for TMR. The Lok Sabha Standing Committee on Chemicals & Fertilizers (33rd Report, Aug 2026) called the delay "inordinate" and asked for a permanent framework within a set time.
  • Enforcement record: of ₹10,013.30 crore in overcharging demands, ₹8,526.10 crore (about 85%) was still unpaid on 30.9.2025.

Don't confuse with

  • Ceiling price: a fixed upper price for scheduled (NLEM) drugs, set by NPPA under Paras 4 & 6. TMR fixes no single price. It caps the margin over each company's own PTD on non-scheduled drugs, so different brands of the same drug can still have different MRPs.
  • Cost-based pricing: a price built up from the actual cost of making the drug. DPCO 2013 moved drug pricing from cost-based to market-based pricing. TMR does not check production cost at all.
  • Manufacturer's profit margin: this is the company's profit within its PTD. The trade margin is what distributors and chemists earn between PTD and MRP. TMR targets only the trade margin.
  • 10% annual price-rise cap: this limits how fast the MRP of a non-scheduled drug can rise. TMR cuts the MRP level by limiting the markup.

Prelims Hooks

  • TMR is carried out under Para 19 of DPCO 2013 (extraordinary circumstances, public interest). It is not a permanent provision of DPCO.
  • DPCO 2013 is issued under Section 3 of the Essential Commodities Act, 1955, not the Drugs & Cosmetics Act, 1940.
  • NPPA (1997) is under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, not MoHFW. It was created by resolution, so it is not a statutory body.
  • TMR applies to non-scheduled drugs. Scheduled (NLEM 2022, 384 medicines) drugs already have ceiling prices.
  • 2019 pilot: 42 anti-cancer drugs, trade margin capped at 30%. 2021: 6 COVID devices, margin capped at 70% of PTD.
  • Trap: "137" is the number of drugs under the 2026 TMR, and "543" is the number of brands with revised MRPs.

Mains Points

  • A middle path between price control and free markets:
  • non-scheduled drugs are about 82% of market value and ceiling prices do not reach them;
  • TMR cuts patient prices but leaves the manufacturer's price and brand competition intact;

  • its limit is that a high factory-gate price escapes it, which is why the Committee suggested considering cost-based pricing where markups are abnormally high.

  • Emergency power vs permanent rule:

  • Para 19 is meant for a limited period;
  • relying on it leaves industry unsure about future rules and invites disputes, e.g. over how the trade margin is deducted from overcharged amounts;

  • a permanent framework could use the WHO 2020 idea of regressive markups, where the allowed percentage falls as the drug's price rises. Cheap rural generics keep enough margin to cover real costs, and costly cancer drugs get a lower one.

  • Affordability vs availability:

  • MSME drug makers warn that margin caps could hurt rural supply chains and small firms;
  • this is a real risk for a blanket cap on all non-scheduled drugs. It is weak for high-priced cancer drugs, where even a modest percentage margin earns many rupees;
  • TMR also works best alongside Jan Aushadhi and AMRIT pharmacies, plus better enforcement against old-stock sales and slow recovery of dues.

Recent developments

  • 2026: the 30% cap scaled up from pilot to wide use. NPPA applied the same 30% trade margin cap used in the 2019 pilot to 137 non-scheduled anti-cancer drugs, about 900 brands in all. That is more than three times the 2019 drug count. The list includes costly immunotherapy drugs (drugs that help the body's own immune system fight cancer), Pegfilgrastim and Denosumab. These are drugs where the manufacturer's own high price (PTD) is most of what the patient pays. This tests how far TMR can go when the factory-gate price is the main cost.
  • 2026: the new MRPs come in stages. The first list of revised MRPs covers only 543 of the roughly 900 brands, and NPPA says it will update the list on a continual basis. Until a brand's new MRP is notified, a patient buying that brand has no fixed lower price to demand.
  • 2026: headline cuts are the best case, not the usual case. The government says MRPs will fall by up to 70%, and the steepest cuts reach about 93% (e.g. one drug fell from ₹40,000 to ₹2,720). In 2019 the average cut was about 50%. Unlike the 2019 figure of ₹984 crore a year, no rupee estimate of patient savings has been given. So the real gain from this bigger round cannot yet be measured.
  • Aug 2026: Parliament found TMR's enforcement weak and asked for fixes. The Standing Committee found that about 70% of NPPA's unpaid overcharging dues are stuck in litigation (court cases), some pending for over 20 years. It recommended a fast-track dispute resolution system for cases not yet in court and a dedicated legal cell inside NPPA. Without this, a company that breaks a TMR order may face no real penalty for years.

Read more